Quality improvement in paediatric radiation oncology through peer review

Laura Murphy1, Jessica Cantwell1, Jennifer Chard1

  • 1Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia.

Insights

A videoconference for pediatric radiation oncologists in Australia and New Zealand (ANZ) can improve patient care. The meeting, held fortnightly, recommended management changes for 13% of pediatric radiation therapy cases reviewed.

Area of Science:

  • Pediatric Oncology
  • Radiation Oncology
  • Clinical Audit

Background:

  • Approximately 300 children in Australia and New Zealand (ANZ) receive radiation treatment (RT) annually.
  • A videoconference for radiation oncologists managing pediatric patients commenced in 2013.
  • This audit assessed the videoconference's impact on pediatric RT care in ANZ.

Purpose of the Study:

  • To audit a fortnightly videoconference for pediatric radiation oncologists in ANZ.
  • To evaluate the videoconference's influence on the management of children receiving RT.
  • To identify potential improvements for pediatric RT services.

Main Methods:

  • Retrospective analysis of de-identified videoconference minutes from August 2013 to December 2019.
  • Data categorized into meeting participation, case presentations, and management decisions.
  • Audit focused on meeting frequency, attendance, case discussion timing, and treatment plan modifications.

Main Results:

  • 119 meetings were held, discussing 334 pediatric patients over six years.
  • Most cases (80%) were discussed before RT initiation.
  • Management plan changes were recommended for 13% of patients, with 8% of RT plans adjusted.

Conclusions:

  • Increasing meeting frequency to weekly could allow review of all pediatric RT patients prior to treatment.
  • The videoconference is crucial for maintaining expertise in pediatric RT and can serve as a proton therapy referral panel.
  • Enhancements could lead to changes in RT management for up to 13% of children annually.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
131
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
113
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
176
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
148